Jacobs Levy Equity Management
CBAY

Jacobs Levy Equity Management’s Cymabay Therapeutics CBAY Stock Holding History

Jacobs Levy Equity Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-171,539
Closed -$985K – 1138
2020
Q4 		$985K Sell
171,539
-51,069
-23% -$387K 0.01% 722
2020
Q3 		$1.61M Sell
222,608
-78,609
-26% -$420K 0.02% 558
2020
Q2 		$1.05M Buy
301,217
+258,617
+607% +$746K 0.01% 663
2020
Q1 		$63K Sell
42,600
-174,009
-80% -$292K ﹤0.01% 973
2019
Q4 		$425K Buy
216,609
+166,759
+335% +$626K ﹤0.01% 806
2019
Q3 		$255K Buy
+49,850
New +$302K ﹤0.01% 804

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jacobs Levy Equity Management's CBAY Position: Q1 2021 in Review

Jacobs Levy Equity Management sold out of Cymabay Therapeutics (CBAY) in Q1 2021, closing a stake of 171,539 shares — an estimated $985K sold.

Jacobs Levy Equity Management first reported a position in CBAY in Q3 2019 and held it in 6 quarters. The position peaked at $1.61M in Q3 2020. 130 funds tracked by Wall St. Rank hold CBAY as of Q1 2021.

  • Jacobs Levy Equity Management reported no remaining Cymabay Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 171,539 Cymabay Therapeutics shares in Q1 2021, an estimated $985K.
  • Jacobs Levy Equity Management first reported a position in Cymabay Therapeutics in Q3 2019 and held it in 6 quarters.
  • Jacobs Levy Equity Management's Cymabay Therapeutics position peaked at $1.61M in Q3 2020.
  • 130 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2021, filed 17 May 2021.